COEP (Coeptis Therapeutics Holdings) EPS (Basic): $-2.76 (TTM As of Dec. 2025)

What is Coeptis Therapeutics Holdings EPS (Basic)?

Coeptis Therapeutics Holdings COEP +1.52% 12 EPS (Basic) is $-2.76 as of Dec. 2025. GuruFocus rates COEP with a GF Score™ of 12/100.

Coeptis Therapeutics Holdings's basic earnings per share (Basic EPS) for the three months ended in Dec. 2025 was $-0.12. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.76.

Coeptis Therapeutics Holdings's EPS (Diluted) for the three months ended in Dec. 2025 was $-0.12. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.76.

Coeptis Therapeutics Holdings's EPS without NRI for the three months ended in Dec. 2025 was $-0.21. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -3.10.

During the past 3 years, the average EPS without NRI Growth Rate was 59.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 22.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Coeptis Therapeutics Holdings's highest 3-Year average EPS without NRI Growth Rate was 59.90% per year. The lowest was -23.80% per year. And the median was 26.30% per year.

Coeptis Therapeutics Holdings (NAS:COEP) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Coeptis Therapeutics Holdings EPS (Basic) Related Terms

Coeptis Therapeutics Holdings EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Coeptis Therapeutics Holdings's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coeptis Therapeutics Holdings EPS (Basic) Chart

Coeptis Therapeutics Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

-13.16

-52.60

-16.56

-5.56

-2.81

Coeptis Therapeutics Holdings Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
EPS (Basic)	Get a 7-Day Free Trial															-1.36	-1.11	-0.95	-0.58	-0.12

12GF Score

Coeptis Therapeutics Holdings Inc COEP

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Coeptis Therapeutics Holdings EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Coeptis Therapeutics Holdings's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-11.917	-	0)	/	4.235
	=	-2.81

Coeptis Therapeutics Holdings's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-1.578	-	0)	/	5.396
	=	-0.29

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.76

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of $-2.76 mean?

Coeptis Therapeutics Holdings (COEP) has a EPS (Basic) of $-2.76 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Coeptis Therapeutics Holdings and its competitors.

Is Coeptis Therapeutics Holdings' EPS (Basic) too high?

Coeptis Therapeutics Holdings' current EPS (Basic) is $-2.76. Overall, Coeptis Therapeutics Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Coeptis Therapeutics Holdings' EPS (Basic) compare to ANIX and COYA?

Coeptis Therapeutics Holdings' EPS (Basic) of $-2.76 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Coeptis Therapeutics Holdings and its competitors. Coeptis Therapeutics Holdings's current EPS (Basic) is $-2.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Coeptis Therapeutics Holdings stock overvalued right now?

Coeptis Therapeutics Holdings (COEP) has a current EPS (Basic) of $-2.76. The current EPS (Basic) is $-2.76. Coeptis Therapeutics Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Coeptis Therapeutics Holdings (COEP), the current EPS (Basic) is $-2.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Coeptis Therapeutics Holdings Business Description

Industry Healthcare Biotechnology

Comparable Companies ANIX COYA PMN TTRX GUTS PEPG NRXP IFRX INO RANI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ASX:CSL ALNY ONC XKRX:068270 INSM

Address 105 Bradford Road, Suite 420, Wexford, PA, USA, 15090

Website https://www.coeptistx.com

Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.

12GF Score

Get the complete analysis for COEP

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.40

Price

View COEP Analysis

See EPS (Basic) data for all stocks →